| 摘要 |
1. Use of treosulfan for the preparation of a pharmaceutical composition for conditioning therapy over a period of 2 to 7 days while administering of the common dose, of at least, 20 g/m<2> body surface area before allogenic transplantation of bone marrow or haematopoietic stem cells. 2. Use according to Claim 1, characterized in that the total dose amounts to 20 to 60 g/m<2> body surface area. 3. Use according 2 Claim 2, characterized in that the total dose amounts to 30 g/m<2> body surface area. 4. Use according to Claim 2, characterized in that the total dose amounts to 42 to 48 g/m<2> body surface area. 5. Use according to Claims 1 to 4, characterized in that the conditioning therapy takes place over a period of 3, 5 or 7 days. 6. Use according to Claims 1 to 4, characterized in that the conditioning therapy takes place in the form of a continuous infusion. 7. Use according to Claims 1 to 4, characterized in that the conditioning therapy takes place in the form of daily individual doses. 8. Use according to Claim 4, characterized in that the pharmaceutical composition is formulated so that it is suitable for the infusion of treosulfan over a period of 2 to 7 days, in each ease for a period of 0.5 to 24 hours per day. 9. Use according to Claims 1 to 8, characterized in that treosulfan is used with at least one further chemotherapeutic agent and/or immunosuppressive agents. 10. Use according to Claim 9, characterized in that the pharmaceutical composition is a combination preparation. 11. Use according to Claim 10, characterized in that the chemotherapeutic agent is a cytostatic agent. 12. Use according to Claim 11, characterized in that the cytostatic agent is selected from the group consisting of cyclophosphamide, thiotepa, melphalan, carboplatin or fludarabine. 13. Use according to Claims 9 to 12, characterized in that the immunosuppressive agents are immunosuppressive antibodies. 14. Use according to Claims 9 to 12 for conditioning therapy with additional whole-body irradiation of the patient. 15. Use according to Claim 12, characterized in that the cytostatic agent is cyclophosphamide, and the pharmaceutical composition is formulated so that it is suitable for the administration of 14 to 16 g treosulfan/m<2> body surface area on each of 3 consecutive days, and of 60 to 100 mg cyclophosphamide/kg body weight on each of the following 2 days.
|
